Decision makers are frequently faced with the question of how realistic are cost-effectiveness models. Overall survival (OS) is a desired clinical trial and health technology assessment endpoint but frequently unrealistic or elusive at the point of new drugs financing decision. We aim to compare the overall survival from lenalidomide treatment in relapsed/refractory multiple myeloma (rrMM) patients estimated from modelling clinical trial data in a costeffectiveness analysis (CEA) and compare it with real-word data (RWD) from South Korea.
RESULTS

MATERIALS & METHODS
. This study provides evidence that overall survival of Lenalidomideplus-dexamethasone treatment in relapsed/refractory multiple myeloma estimated in a cost-effectiveness analysis is remarkably similar to the outcomes observed in real-word patients and points to the value of such upfront estimates to decision makers in the absence of mature clinical trials data.
CONCLUSIONS
